{
  "report_rows": [
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$3.42 vs. cons $3.34",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted operating income",
      "prediction": "BEAT",
      "answer": "pred ~$565M vs. cons $553M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "U.S. dialysis treatments per normalized day growth (YoY)",
      "prediction": "BEAT",
      "answer": "pred ~0.95% vs. cons 0.75%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 adjusted operating income guidance",
      "prediction": "BETTER",
      "answer": "guide ~$2.23B midpoint vs. cons $2.21B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 adjusted diluted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$14.95 midpoint vs. cons $14.83 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 treatment-volume growth guidance",
      "prediction": "BETTER",
      "answer": "guide ~0.60% midpoint vs. cons 0.45% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 free-cash-flow guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$1.13B midpoint vs. cons $1.13B (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 3.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 2.0,
  "day5_path": "FADE",
  "day5_rationale": "A ~$0.08 EPS beat and modest FY2026 guide increase support an initially positive ~3.2% residual reaction, but the guide uplift is likely largely volume/productivity driven and only ~1% above consensus. The market will continue to discount second-half commercial-mix and ACA pressure, limiting out-period estimate revisions; residual gains fade from ~3.2% on day 1 to ~2.0% by day 5.",
  "day5_confidence": "MEDIUM"
}